ATE345803T1 - Neue methoden unter verwendung von cholinesteraseinhibitoren - Google Patents

Neue methoden unter verwendung von cholinesteraseinhibitoren

Info

Publication number
ATE345803T1
ATE345803T1 AT01922272T AT01922272T ATE345803T1 AT E345803 T1 ATE345803 T1 AT E345803T1 AT 01922272 T AT01922272 T AT 01922272T AT 01922272 T AT01922272 T AT 01922272T AT E345803 T1 ATE345803 T1 AT E345803T1
Authority
AT
Austria
Prior art keywords
cholinesterase inhibitors
new methods
cholinesterase
inhibitors
donepezil
Prior art date
Application number
AT01922272T
Other languages
English (en)
Inventor
Raymond Pratt
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of ATE345803T1 publication Critical patent/ATE345803T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01922272T 2000-03-03 2001-03-05 Neue methoden unter verwendung von cholinesteraseinhibitoren ATE345803T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18674400P 2000-03-03 2000-03-03
US19761000P 2000-04-18 2000-04-18
US22078300P 2000-07-25 2000-07-25
US25922601P 2001-01-03 2001-01-03

Publications (1)

Publication Number Publication Date
ATE345803T1 true ATE345803T1 (de) 2006-12-15

Family

ID=27497683

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01922272T ATE345803T1 (de) 2000-03-03 2001-03-05 Neue methoden unter verwendung von cholinesteraseinhibitoren

Country Status (11)

Country Link
US (7) US20020035128A1 (de)
EP (5) EP2130538A1 (de)
JP (1) JP2003525903A (de)
AT (1) ATE345803T1 (de)
AU (1) AU2001249091A1 (de)
CY (1) CY1107997T1 (de)
DE (1) DE60124730T2 (de)
DK (1) DK1311272T3 (de)
ES (1) ES2275670T3 (de)
PT (1) PT1311272E (de)
WO (1) WO2001066114A1 (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
WO2001066114A1 (en) * 2000-03-03 2001-09-13 Eisai Co., Ltd. Novel methods using cholinesterase inhibitors
EP1372620A2 (de) * 2001-03-15 2004-01-02 Saegis Pharmaceuticals Verfahren zur wiederherstellung der kognitiven funktion nach systemischem stress
WO2003020289A1 (en) * 2001-08-30 2003-03-13 Ortho-Mcneil Pharmaceutical, Inc. Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
WO2003032914A2 (en) * 2001-10-17 2003-04-24 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
EP1468684A4 (de) * 2002-01-22 2008-02-27 Eisai R&D Man Co Ltd Sigma-rezeptor-bindungsmolekül mit indanonderivat
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20070053976A1 (en) * 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
AU2003298514A1 (en) * 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20060129385A1 (en) * 2002-07-22 2006-06-15 Heller James H Cholinergic therapy for individuals with learning disabilities
WO2004041281A1 (en) * 2002-11-01 2004-05-21 Oregon Health And Science University Treatment of hyperkinetic movement disorder with donepezil
WO2004075916A1 (en) * 2003-02-27 2004-09-10 Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. Pharmaceutical composition for treatment of drug dependence
AU2004233863B2 (en) * 2003-04-24 2010-06-17 Incyte Holdings Corporation Aza spiro alkane derivatives as inhibitors of metalloproteases
US9119846B2 (en) * 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
CA2567746A1 (en) * 2003-05-23 2005-01-06 Cognition Pharmaceuticals Llc Methods for treating cognitive impairment and improving cognition
ES2305776T3 (es) 2003-06-17 2008-11-01 Pfizer Inc. Derivados de n-pirrolidin-3-il-amida como inhibidores de la re-captacion de serotonina y noradrenalina.
JPWO2005027968A1 (ja) * 2003-09-19 2007-11-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 ダウン症候群治療剤
CA2552221A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
EP1743036A4 (de) * 2004-01-22 2008-07-02 Genaissance Pharmaceuticals Mit dem alter bei erstauftreten von alzheimer im zusammenhang stehende apoe-genmarker
US20050228019A1 (en) * 2004-01-26 2005-10-13 Cortex Pharmaceuticals, Inc. Enhancement of ampakine-Induced facilitation of synaptic responses by cholinesterase inhibitors
CA2553033A1 (en) * 2004-01-30 2005-08-18 Axonyx, Inc. Methods for treatment of complications of diabetes
US20060106060A1 (en) * 2004-03-18 2006-05-18 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
EP1744751A4 (de) * 2004-03-18 2010-03-10 Brigham & Womens Hospital Verfahren zur behandlung von synucleinopathien
JP2007529555A (ja) * 2004-03-18 2007-10-25 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド シヌクレイノパチーを治療する方法
TW200533371A (en) * 2004-04-15 2005-10-16 Dainippon Pharmaceutical Co Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
US20060135507A1 (en) * 2004-08-13 2006-06-22 Osamu Yokoyama Therapeutic agent for overactive bladder involved in aging
WO2006037047A2 (en) * 2004-09-27 2006-04-06 Bridge Pharma, Inc. The r-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
US7718674B2 (en) * 2004-09-27 2010-05-18 Bridge Pharma, Inc. Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine
ATE511843T1 (de) * 2005-04-04 2011-06-15 Eisai R&D Man Co Ltd Dihydropyridin-verbindungen für neurodegenerative erkrankungen und demenz
GB0605544D0 (en) * 2006-03-20 2006-04-26 Univ Nottingham Genetic Markers For Alzheimer Disease
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
WO2008011161A2 (en) * 2006-07-21 2008-01-24 Bridge Pharma, Inc. Dermal anesthetic compounds
US8012994B1 (en) 2006-09-22 2011-09-06 Sevastyanov Victor V Method for the treatment of sensorineural hearing loss with donepezil hydrochloride (ARICEPT®)
JP5237112B2 (ja) * 2006-12-01 2013-07-17 日東電工株式会社 経皮吸収製剤
KR101408454B1 (ko) * 2006-12-01 2014-06-17 닛토덴코 가부시키가이샤 도네페질 함유 접착 제제의 착색을 억제하는 방법 및 도네페질의 친척 물질의 생성량을 감소시키는 방법
US20100099714A1 (en) * 2007-03-05 2010-04-22 Eisai R&D Management Co., Ltd. AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases
US20100130537A1 (en) * 2007-04-26 2010-05-27 Eisai R&D Management Co., Ltd Cinnamide compounds for dementia
CA2685860A1 (en) * 2007-05-10 2008-11-20 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
CA2703563A1 (en) * 2007-10-31 2009-05-07 Alseres Pharmaceuticals, Inc. Methods for diagnosing and monitoring treatment of lewy body dementia by assessing dopamine transporter level
US20090156561A1 (en) * 2007-12-13 2009-06-18 Seed John C Use of Cholinesterase Inhibitors In Smoking Cessation
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
US20090291127A1 (en) * 2008-05-21 2009-11-26 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
RU2481826C2 (ru) * 2008-05-30 2013-05-20 Нитто Денко Корпорейшн Содержащий донепезил адгезивный препарат и упаковка для него
RU2483729C2 (ru) * 2008-05-30 2013-06-10 Нитто Денко Корпорейшн Чрескожно абсорбируемый препарат
WO2010039381A1 (en) * 2008-09-30 2010-04-08 Teikoku Pharma Usa, Inc. Transdermal extended-delivery donepezil compositions and methods for using the same
MX2011005096A (es) * 2008-11-13 2011-11-18 Link Medicine Corp Derivados de azaquinolinona y usos de los mismos.
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
BRPI1013777A8 (pt) * 2009-04-13 2017-09-19 Theravance Biopharma R&D Ip Llc Compostos agonistas do receptor 5-ht4 para tratamento de distúrbios cognitivos.
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
US20110212928A1 (en) 2010-02-09 2011-09-01 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2366378A1 (de) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Donepezilformulierungen mit verzögerter Freisetzung
WO2011127235A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
GR1007368B (el) 2010-05-27 2011-08-02 Alapis Α.Β.Ε.Ε., Ποσιμα φαρμακευτικα διαλυματα για τη θεραπεια των συμπτωματων της ανοιας
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
EP2642998B1 (de) 2010-11-24 2020-09-16 The Trustees of Columbia University in the City of New York Non-retinoider rbp4-antagonist zur behandlung von altersbedingter makuladegeneration und morbus stargardt
US20120225922A1 (en) 2011-03-04 2012-09-06 Qr Pharma Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration
US9265738B2 (en) 2012-01-20 2016-02-23 The Board Of Trustees Of The Leland Stanford Junior University Small molecule CMKLR1 antagonists in demyelinating disease
WO2013166037A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of eye disorders
WO2014078568A1 (en) * 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
ES2700541T3 (es) 2013-03-14 2019-02-18 Univ Columbia Octahidrociclopentapirroles, su preparación y uso
WO2014152013A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
EP2968220B1 (de) 2013-03-15 2021-05-05 Agenebio, Inc. Verfahren und zusammensetzungen zur verbesserung von kognitiven funktionen
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
US9359315B2 (en) 2013-09-10 2016-06-07 Arrien Pharmaceuticals Llc Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
DK4036094T3 (da) 2014-04-30 2026-03-23 Univ Columbia Erstattede 4-fenylpiperidiner, deres fremstilling og anvendelse
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
TWI698436B (zh) 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
HK1248221A1 (zh) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 异噻唑啉酮类，吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂
HK1248222A1 (zh) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 噻吩并嘧啶酮作为泛素特异性蛋白酶7抑制剂
HK1248220A1 (zh) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 喹唑啉酮和偶氮喹唑啉作为泛特丁胺蛋白酶7抑制剂
NZ738682A (en) 2015-05-22 2022-01-28 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam
CA2994974C (en) * 2015-08-14 2024-04-09 Qr Pharma Methods of treatment or prevention of acute brain or nerve injuries
US20180338950A1 (en) 2017-05-24 2018-11-29 Qr Pharma, Inc. Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis Via Administration of Posiphen to Healthy or Sick Humans
JP2021501210A (ja) 2017-10-30 2021-01-14 モントリオール ハート インスティテュート 血漿コレステロールの上昇を処置する方法
RS67299B1 (sr) * 2018-06-19 2025-11-28 Univ Pablo De Olavide Kompozicije za lečenje i/ili prevenciju bolesti agregacije proteina
PH12021551324A1 (en) 2019-01-08 2022-04-25 Kyorin Seiyaku Kk 15-pgdh inhibitor
US12304897B2 (en) 2019-01-31 2025-05-20 Kyorin Pharmaceutical Co., Ltd. 15-PGDH inhibitors
JP2022541021A (ja) * 2019-07-16 2022-09-21 ラッシュ・ユニバーシティ・メディカル・センター 神経変性障害を治療するためのベンゾエート含有組成物の使用
US12582632B2 (en) 2021-05-18 2026-03-24 Annovis Bio, Inc. Inhibition of neurological injuries due to infections via administration of Butanetap and analogs thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
US4826843A (en) * 1985-07-08 1989-05-02 Bristol-Myers Cerebral function enhancing diazinylpiperidine derivatives
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JP2777159B2 (ja) * 1988-12-22 1998-07-16 エーザイ株式会社 環状アミン誘導体を含有する医薬
JP3075566B2 (ja) 1990-05-15 2000-08-14 エーザイ株式会社 光学活性インダノン誘導体
JP2965675B2 (ja) 1990-11-21 1999-10-18 エーザイ株式会社 （―）―１―ベンジル―４―〔（５，６―ジメトキシ―１―インダノン）―２―イル〕メチルピペリジンの製造方法
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
CA2113115A1 (en) * 1991-07-29 1993-02-18 Vlad E. Gregor Quinazoline derivatives as acetylcholinesterase inhibitors
SE9103752D0 (sv) * 1991-12-18 1991-12-18 Astra Ab New compounds
ES2188946T3 (es) 1996-06-07 2003-07-01 Eisai Co Ltd Polimorfos de clorhidrato de donepecil y proceso de fabricacion de los mismos.
WO1997046526A1 (en) 1996-06-07 1997-12-11 Eisai Co., Ltd. Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
TW513409B (en) 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
AU4078997A (en) * 1996-08-22 1998-03-06 New York University Cholinesterase inhibitors for treatment of parkinson's disease
DK0971713T3 (da) 1997-03-03 2003-09-22 Eisai Co Ltd Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
EP1017375A2 (de) * 1997-09-24 2000-07-12 Nova Molecular, Inc. Methoden zum erhöhen des apoe-spiegels zur behandlung von neurodegenerativen krankheiten
EP1048653B1 (de) 1997-12-05 2004-03-03 Eisai Co., Ltd. Donepezil polykristalle und verfharen zu ihrer herstellung
WO1999036405A1 (en) 1998-01-16 1999-07-22 Eisai Co., Ltd. Process for production of donepezil derivative
US6193993B1 (en) 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
US6576677B1 (en) 1998-08-28 2003-06-10 Eisai Co., Ltd. Medicinal compositions with relieved bitterness
IT1304904B1 (it) 1998-09-11 2001-04-05 Eisai Co Ltd Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche
ES2211056T3 (es) 1999-03-31 2004-07-01 Eisai Co., Ltd. Composiciones estabilizadas que contienen farmacos nootropicos.
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
WO2001066114A1 (en) * 2000-03-03 2001-09-13 Eisai Co., Ltd. Novel methods using cholinesterase inhibitors
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
US20030144255A1 (en) 2000-03-06 2003-07-31 Bain Allen I Compositions for prevention and treatment of dementia
US20010036949A1 (en) 2000-05-09 2001-11-01 Coe Jotham Wadsworth Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
WO2003024456A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating and preventing migraines
WO2003024450A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
WO2003032914A2 (en) 2001-10-17 2003-04-24 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
GB2405336A (en) 2002-05-01 2005-03-02 Eisai Co Ltd Cholinesterase inhibitors to prevent injuries caused by chemicals
AU2003298514A1 (en) 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
WO2004041281A1 (en) * 2002-11-01 2004-05-21 Oregon Health And Science University Treatment of hyperkinetic movement disorder with donepezil

Also Published As

Publication number Publication date
DE60124730D1 (de) 2007-01-04
PT1311272E (pt) 2007-02-28
JP2003525903A (ja) 2003-09-02
US20040122051A1 (en) 2004-06-24
CY1107997T1 (el) 2013-09-04
AU2001249091A1 (en) 2001-09-17
US6482838B2 (en) 2002-11-19
ES2275670T3 (es) 2007-06-16
US20050250812A1 (en) 2005-11-10
US20020035128A1 (en) 2002-03-21
US6689795B2 (en) 2004-02-10
US20030040532A1 (en) 2003-02-27
DK1311272T3 (da) 2007-02-26
US20020040038A1 (en) 2002-04-04
EP1311272B1 (de) 2006-11-22
US6576646B1 (en) 2003-06-10
DE60124730T2 (de) 2007-10-04
US6458807B1 (en) 2002-10-01
EP2138177A1 (de) 2009-12-30
US7563808B2 (en) 2009-07-21
EP1311272A4 (de) 2003-05-21
EP1311272A1 (de) 2003-05-21
EP2133078A1 (de) 2009-12-16
US20020035129A1 (en) 2002-03-21
EP2130538A1 (de) 2009-12-09
WO2001066114A1 (en) 2001-09-13
EP2140868A1 (de) 2010-01-06

Similar Documents

Publication Publication Date Title
DE60124730D1 (de) Neue methoden unter verwendung von cholinesteraseinhibitoren
UY26820A1 (es) Derivados de ciclopentil-glutaramida como inhibidores de endopeptidasa neutra
ATE360884T1 (de) Vorrichtung zum behandeln eines scheibenförmigen gegenstandes
CY1114058T1 (el) Μεθοδος παρασκευης οπτικως καθαρων δραστικων ενωσεων
DE50011437D1 (de) Verfahren zur Erzeugung von Justiermarken
ATE411030T1 (de) Phosphonatanaloga von hiv- integrasehemmerverbindungen
DE69919700D1 (de) Überbrückte indenopyrrolocarbazole
BR0307977A (pt) Composição alvejante
ATE455778T1 (de) Verfahren zur herstellung form i von (s)-(+)- clopidogrelbisulfat
DK0785949T3 (da) Fremgangsmåde til oprensning af keratinocytvækstfaktorer
DE60325194D1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
PL377441A1 (pl) Sposób wytwarzania stereoizomeru glikopironiowego o konfiguracji R,R (lub S,S)
DK1206452T3 (da) Fremgangsmåde til fremstilling af benzoperhydro-isoindolforbindelser
ATE499481T1 (de) Verfahren zum bleichen unter verwendung von einer lipophilen flüssigkeit
EA199801084A1 (ru) Спосб получения фенилгетероциклических соединений, используемых в качестве ингибиторов циклооксигеназы-2
ZA976854B (en) Treatment of psychotic disorders.
DK1280752T3 (da) Fremgangsmåde til fremstilling af 2-alkyl-3-chlorphenoler
ATE283367T1 (de) Verfahren zur gewinnung von bakteriorhodopsin
ATE380183T1 (de) Verfahren zur herstellung von phenyltetrazolderivaten
ATE425143T1 (de) Verfahren zur herstellung von indolen
DK1070022T3 (da) Apparatur til behandling af vand
DK1496891T3 (da) Fremgangsmåder til modulering af fototoksicitet
ATE319241T1 (de) Verfahren zur erzeugung eines asymmetrischen kryptografischen gruppenschlüsselpaares
DE60332366D1 (de) Stabile faltungszwischenverbindung von apolipoprotein e und verfahren zur verwendung davon
ATE325111T1 (de) Verfahren zur herstellung von 15-pentadecanolid

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1311272

Country of ref document: EP